- Work/Life Balance
- Culture & Values
- Career Opportunities
- Comp & Benefits
- Senior Management
I worked at Icagen full-time (More than 3 years)RecommendsNeutral OutlookApproves of CEORecommendsNeutral OutlookApproves of CEO
Great people and a can do attitude. Was fun to progress compounds that could make it to the clinic and serve patients
Because of small size opportunity for advancement was limited. Management was very micro-managing and not very trusting of the expertise of the staff they hired.
Advice to Management
Culture would have benefited from being less micro-managerial
Let us know if we're missing any workplace or industry recognition –
Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with Johnson & Johnson subsidiary McNeil Consumer & Specialty Pharmaceuticals. Shortly thereafter Icagen announced a deal collaborating with ...